Corvus Pharmaceuticals (CRVS) Short-term Investments (2024 - 2026)

Corvus Pharmaceuticals' Short-term Investments history runs 3 years deep, the most recent figure standing at $196.6 million for Q1 2026.

• In Q1 2026, Short-term Investments changed N/A year-over-year to $196.6 million; the TTM figure through Mar 2026 stood at $196.6 million (changed N/A YoY), while the FY2025 annual figure was $52.2 million, up 20.71% from the prior year.
• Short-term Investments was $196.6 million for Q1 2026 at Corvus Pharmaceuticals, up from $52.2 million in the prior quarter.
• In the past five years, Short-term Investments ranged from a high of $196.6 million in Q1 2026 to a low of $43.2 million in Q4 2024.
• Historically, Short-term Investments has averaged $97.3 million across 3 years, with a median of $52.2 million in 2025.
• Biggest YoY gain for Short-term Investments was 20.71% in 2025; the steepest drop was 20.71% in 2025.
• A 3-year view of Short-term Investments shows it stood at $43.2 million in 2024, then increased by 20.71% to $52.2 million in 2025, then soared by 276.84% to $196.6 million in 2026.
• The last three Short-term Investments figures came in at $196.6 million (Q1 2026), $52.2 million (Q4 2025), and $43.2 million (Q4 2024), per Business Quant data.